Dimerix Limited (ASX:DXB) Receives Initial Upfront Payment from FUSO
Financial and Development Milestones
Dimerix Limited has received an initial upfront payment of ¥300 million (~AU$3.2 million) from FUSO Pharmaceutical Industries, Ltd. The company anticipates a further ¥400 million (~AU$4.1 million) upon achieving the first development milestone, expected within the next 6-12 weeks. Additionally, Dimerix remains eligible for potential development milestones of up to ¥3 billion (~AU$30.6 million) and sales milestones of up to ¥6.8 billion (~AU$69.4 million), along with 15–20% royalties on net sales of DMX-200.
Licensing Agreements and Future Focus
With FUSO, Advanz Pharma, and Taiba, Dimerix has secured three high-quality license deals, collectively providing up to ~AU$458 million in upfront payments and potential milestone payments, plus royalties on net sales. The company continues to pursue licensing opportunities in territories not covered by existing agreements, including major markets such as the US and China.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.